After putting on a strong performance in preventing disease progression in the earlier treatment of multiple myeloma, Johnson ...

Bristol Myers Squibb’s struggling CAR-T therapy Abecma has hit a major setback. | Bristol Myers Squibb’s CAR-T therapy Abecma ...

KarMMa-9 trial for Abecma, saving $80 million and focusing on profitability by 2025. Despite the decision, the company ...

Abecma (idecabtagene vicleucel) is prescribed to treat multiple myeloma in certain cases. The drug comes as a suspension (liquid mixture) made from your body’s cells. You receive it by ...

(TSVT) stock lost as company with Bristol Myers Squibb (BMY) plan to discontinue enrollments in a Phase 3 trial for cancer ...

Johnson & Johnson linked Carvykti to a 45% reduction in risk of death and Darzalex to a 61% improvement in minimal residual ...

BMY decide to stop enrollment in the late-stage study on Abecma due to growth in the newly diagnosed multiple myeloma treatment space.

The study is evaluating Abecma (idecabtagene vicleucel; ide-cel) with Revlimid (lenalidomide) maintenance versus lenalidomide maintenance alone in patients with newly diagnosed multiple myeloma ...

CAMBRIDGE, Mass., September 25, 2024--2seventy bio, Inc. (Nasdaq: TSVT) today announced that the Company, in partnership with ...

Abecma, developed in partnership with Bristol-Myers Squibb, for treating patients with newly diagnosed multiple myeloma.